GLPwatch
Trulicity for MASH (metabolic dysfunction-associated steatohepatitis)
dulaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCTrulicity (dulaglutide) is not FDA-approved for MASH (metabolic dysfunction-associated steatohepatitis), and any use for this condition is off-label or investigational. Research includes studies showing dulaglutide may reduce liver fat and improve liver function markers in patients with type 2 diabetes and NAFLD, as well as animal studies demonstrating potential benefits in metabolic syndrome and hepatic steatosis.
AI summary of the sources below.
| Drug | Trulicity (dulaglutide) |
|---|---|
| Condition | MASH (metabolic dysfunction-associated steatohepatitis) |
| Approval status | Investigational / off-label |
| Research papers | 8 |
Trulicity is not FDA-approved for mash (metabolic dysfunction-associated steatohepatitis); the research below reflects investigational or off-label study only.
Research on dulaglutide for mash (metabolic dysfunction-associated steatohepatitis) (8)
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
- Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
- Resveratrol and Dulaglutide ameliorate adiposity and liver dysfunction in rats with diet-induced metabolic syndrome: Role of SIRT-1 / adipokines / PPARγ and IGF-1.
- Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway.
- Comparative effectiveness of semaglutide <i>versus</i> liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.
- Effects of the switch from dulaglutide to tirzepatide on glycemic control, body weight, and fatty liver: a retrospective study.
- The GLP-1 Receptor Agonist Dulaglutide Attenuates Hepatic Steatosis in Obesity via a Weight-Independent Mechanism.
- Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.